Journal Logo

June 2022 - Volume 32 - Issue 3
pp: 135-210


Clinical Research


Clinicopathological features and programmed death-ligand 1 immunohistochemical expression in a multicenter cohort of uterine and ovarian melanomas: a retrospective study in Japan (KCOG-G1701s)

Yano, Mitsutake; Nasu, Kaei; Yasuda, Masanori; More

Melanoma Research. 32(3):150-158, June 2022.

A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

Awada, Gil; Schwarze, Julia Katharina; Tijtgat, Jens; More

Melanoma Research. 32(3):183-191, June 2022.


Clinical Research


Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases

Ingen-Housz-Oro, Saskia; Milpied, Brigitte; Badrignans, Marine; More

Melanoma Research. 32(3):205-210, June 2022.